Accede al análisis completo con tu suscripción
Últimos 20 reportes · 10-K · 10-K/A · 10-Q · 8-K · Fuente: SEC EDGAR
Accede al análisis completo con tu suscripción
SEC CIK: 0001944048
At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno ® , BAND-AID ® Brand, Johnson’s ® , Listerine ® , Neutrogena ® , Nicorette ® , Tylenol ® , and Zyrtec ® —is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands. Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products, allowing us to connect with consumers across North America, Asia Pacific (“APAC”), Europe, Middle East, and Africa (“EMEA”), and Latin America (“LATAM”) in their daily rituals and the moments that matter most. Our products are marketed across more than 165 countries worldwide.
Ver másConsenso de Analistas
Precio Objetivo — 12 meses
$18.00
Mínimo
-6.1%
$19.00
Mediana
-0.9%
$19.50
Promedio
+1.7%
$23.00
Máximo
+20.0%
| Métrica | LTM jun 26 | 2025 | 2024 | 2023 | 🔒Premium |
|---|---|---|---|---|---|
| INGRESOS Y MÁRGENES | |||||
| Ingresos Totales | 15.408B | 15.124B | 15.455B | 15.444B | 🔒 |
| Cost of Revenue | 6.442B | 6.332B | 6.496B | 6.801B | 🔒 |
| Gross Profit | 8.966B | 8.792B | 8.959B | 8.643B | 🔒 |
| Gross Margin | 58.2% | 58.1% | 58.0% | 56.0% | 🔒 |
| GASTOS OPERATIVOS | |||||
| SG&A / Opex | 6.037B | 6.088B | 6.329B | 6.141B | 🔒 |
| Depreciación & Amort. | 567.000M | 557.000M | 622.000M | 627.000M | 🔒 |
| Operating Income | 2.630B | 2.414B | 1.841B | 2.512B | 🔒 |
| Operating Margin | 17.1% | 16.0% | |||
| STOCK-BASED COMPENSATION | |||||
| Stock-Based Compensation | 116.000M | 136.000M | 254.000M | 188.000M | 🔒 |
| SBC / Revenue | 0.8% | 0.9% | 1.6% | 1.2% | 🔒 |
| RESULTADO NETO | |||||
| Pretax Income | 2.223B | 1.999B | 1.415B | 2.190B | 🔒 |
| Interest Expense (P&L) | 425.000M | — | — | — | 🔒 |
| Tax Expense | 565.000M | 529.000M | 385.000M | 526.000M | 🔒 |
| Beneficio Neto | 1.658B | 1.470B | |||
| INVENTARIO | |||||
| Inventario Neto | 1.722B | 1.666B | 1.591B | 1.851B | 🔒 |
| Inventario / Revenue | 11.2% | 11.0% | 10.3% | 12.0% | 🔒 |
| LIQUIDEZ E INVERSIONES | |||||
| Cash & Equivalentes | 1.110B | 1.062B | 1.070B | 1.382B | 🔒 |
| Total Liquid Assets | 1.110B | 1.062B | 1.070B | 1.382B | 🔒 |
| BALANCE — ACTIVOS | |||||
| PP&E Neto | 2.226B | 2.212B | 1.849B | 2.042B | 🔒 |
| Goodwill | 9.265B | 9.509B | 8.843B | 9.271B | 🔒 |
| Intangibles | 8.406B | 8.694B | 8.474B | 9.619B | 🔒 |
| Activo Total | 26.735B | 27.076B | |||
| CAPITAL Y DEUDA | |||||
| Deuda Total | 8.480B | 8.524B | 8.607B | 8.286B | 🔒 |
| Net Debt | 7.370B | 7.462B | 7.537B | 6.904B | 🔒 |
| Patrimonio Neto | 10.553B | 10.765B | 9.668B | 11.211B | 🔒 |
| Invested Capital | 19.033B | 18.782B | |||
| FLUJO DE CAJA Y CAPEX | |||||
| Cash Flow Operativo (CFO) | 2.325B | 2.197B | 1.769B | 3.168B | 🔒 |
| Capex | 411.000M | 475.000M | 434.000M | 469.000M | 🔒 |
| Free Cash Flow (FCF) | 1.914B | 1.722B | 1.335B | 2.699B | 🔒 |
| FCF Margin | 12.4% | 11.4% | |||
| RATIOS | |||||
| ROIC (NOPAT / IC) | 10.3% | 9.4% | 7.1% | 7.9% | 🔒 |
| Gross Margin | 58.2% | 58.1% | 58.0% | 56.0% | 🔒 |
| Inventario / Revenue | 11.2% | 11.0% | 10.3% | 12.0% | 🔒 |
| ROE (avg equity) | 15.6% | 14.4% | |||
Cifras en miles de millones (B) · Fuente: SEC/EDGAR
| 11.9% |
| 16.3% |
| 🔒 |
| 1.030B |
| 1.664B |
| 🔒 |
| Margen Neto | 10.8% | 9.7% | 6.7% | 10.8% | 🔒 |
| EPS Diluido | 0.85 | 0.76 | 0.54 | 0.90 | 🔒 |
| EPS Básico | 0.86 | 0.77 | 0.54 | 0.90 | 🔒 |
| 25.601B |
| 27.851B |
| 🔒 |
| Pasivo Total | 16.182B | 16.311B | 15.933B | 16.640B | 🔒 |
| 18.886B |
| 24.137B |
| 🔒 |
| Acciones en Circulación | 1.921B | 1.916B | 1.914B | 1.915B | 🔒 |
| 8.6% |
| 17.5% |
| 🔒 |
| NOPAT | 1.962B | 1.775B | 1.340B | 1.909B | 🔒 |
| Recompras de acciones | 70.000M | 197.000M | 235.000M | 7.000M | 🔒 |
| Dividendos pagados | 1.592B | 1.581B | 1.552B | 766.000M | 🔒 |
| Dividendos por acción | 0.83 | 0.82 | 0.81 | 0.40 | 🔒 |
| 9.9% |
| 10.5% |
| 🔒 |
| ROA (avg assets) | 6.2% | 5.6% | 3.9% | 6.0% | 🔒 |
| Operating Margin | 17.1% | 16.0% | 11.9% | 16.3% | 🔒 |
| Margen Neto | 10.8% | 9.7% | 6.7% | 10.8% | 🔒 |
| FCF Margin | 12.4% | 11.4% | 8.6% | 17.5% | 🔒 |
| Effective Tax Rate | 25.4% | 26.5% | 27.2% | 24.0% | 🔒 |
| Debt / Equity Ratio | 0.80x | 0.79x | 0.89x | 0.74x | 🔒 |
Precio actual · USD
$19.17
P/E LTM
22.55
Precio / EPS LTM diluido
ROIC (NOPAT / IC)
10.3%
NOPAT / (Equity + Debt)
Gross Margin
58.2%
Gross profit / Ingresos
Inventario / Revenue
11.2%
Inventario / Ingresos
ROE (avg equity)
15.6%
Benef. neto / Patrimonio
ROA (avg assets)
6.2%
Benef. neto / Activo total
Operating Margin
17.1%
Op. income / Ingresos
Margen Neto
10.8%
Benef. neto / Ingresos